Arbutus Biopharma Corporation (ABUS) analyst actions
Rating and price-target actions on ABUS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ABUS overview →
1 measured ABUS analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders | Press release | -1.90% | +0.00% |
Keep exploring
More ABUS: earnings → · SEC filings → · ABUS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| BeiGene, Ltd. - American Depositary Shares (BGNE) | 191 | +0.11% | 52% |
| CYTODYN INC (CYDY) | 191 | -0.07% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.